Juvenile idiopathic arthritis future or investigational therapies
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dheeraj Makkar, M.D.[2] Nehal Eid, M.D.[3]
|
Juvenile idiopathic arthritis Microchapters |
|
Differentiating Juvenile idiopathic arthritis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Juvenile idiopathic arthritis future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Juvenile idiopathic arthritis future or investigational therapies |
|
FDA on Juvenile idiopathic arthritis future or investigational therapies |
|
CDC on Juvenile idiopathic arthritis future or investigational therapies |
|
Juvenile idiopathic arthritis future or investigational therapies in the news |
|
Blogs on Juvenile idiopathic arthritis future or investigational therapies |
|
Directions to Hospitals Treating Juvenile idiopathic arthritis |
Future and Investigational Therapies
Ongoing research in juvenile idiopathic arthritis (JIA) focuses on improving disease control, reducing treatment-related toxicity, and achieving sustained remission through targeted and personalized therapies. Advances in understanding disease pathogenesis have led to the development of novel biologic and small-molecule agents.
Research registries have been used to quantify rare adverse events incidence such as opportunistic infections and cancer.[1][2] [3]They also provide data and matched controls for observational comparative-effectiveness trials.[4]
Targeted Cytokine Inhibition
- Expansion of interleukin-1 and interleukin-6 inhibitor strategies, including earlier use in systemic JIA
- Investigation of alternative cytokine targets involved in innate and adaptive immune pathways
- Optimization of dosing strategies to improve long-term safety and durability of response
- Since Macrophage activation syndrome pathogensis results from Interferon--γ production, it's proposed to be a treatment target.
Janus Kinase (JAK) Inhibitors
- Oral targeted synthetic DMARDs that inhibit intracellular cytokine signaling
- Under investigation for refractory polyarticular and systemic JIA
- Potential advantages include oral administration and rapid onset of action
- Long-term safety in pediatric populations remains under active evaluation
Precision and Biomarker-Guided Therapy
- A systematic review has shown that 30 to 100% of JIA patients get disease flare after discontinuation of treatment.[5] 50% of these patients cannot regain disease control. [6][7] This raises the question of suitable timing to stop treatment.
- The issue of personalizing treatment is currently being addressed by two international studies:
- The UCAN CAN-DU study (NCT06560606) is exploring the biologic predictors of treatment response, disease course, and remission.
- The SMART-JIA trial (NCT06654882) will assess 4 medications with different mechanisms of action for polyarticular JIA patients not responding to initial TNF-inhibitor therapy.
Tolerance-Inducing and Disease-Modifying Strategies
- Research into immune tolerance restoration to achieve drug-free remission
- Exploration of early aggressive therapy to alter disease trajectory:
- LIMIT-JIA trial is conducted currently to explore whether early biologic DMARD treatment in oligoarticular arthritis patients can prevent progression to polyarthritis or uveitis (ClinicalTrials.gov number, NCT03841357).
- Investigation of mechanisms to prevent progression from systemic inflammation to chronic arthritis in systemic JIA
Emerging Areas
- Novel biologic agents targeting costimulatory pathways
- Cellular and gene-based therapies in early investigational stages
- Long-term studies evaluating optimal timing for therapy withdrawal
Future therapies aim to shift management toward earlier remission, reduced cumulative immunosuppression, and improved quality of life for children with JIA.
Lung disease
Lung disease is still understudied in terms of pathogenesis, as well as effective approaches to identification, screening, and management.[8][9][10]
References
- ↑ Lionetti G, Kimura Y, Schanberg LE, et al. Using registries to identify adverse events in rheumatic diseases. Pediatrics 2013;132(5):e1384-1394.
- ↑ Armaroli G, Klein A, Ganser G, et al. Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry. Arthritis Res Ther 2020; 22: 258
- ↑ Swart J, Giancane G, Horneff G, et al. Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries. Arthritis Res Ther 2018; 20: 285.
- ↑ Ringold S, Nigrovic PA, Feldman BM, et al. The Childhood Arthritis and Rheuma tology Research Alliance consensus treat ment plans: toward comparative effective ness in the pediatric rheumatic diseases. Arthritis Rheumatol 2018; 70: 669-78.
- ↑ Halyabar O, Mehta J, Ringold S, Rum sey DG, Horton DB. Treatment withdraw al following remission in juvenile idio pathic arthritis: a systematic review of the literature. Paediatr Drugs 2019; 21: 469-92.
- ↑ Chang MH, Fuhlbrigge RC, Nigrovic PA. Joint-specific memory, resident memory T cells and the rolling window of opportunity in arthritis. Nat Rev Rheumatol 2024; 20: 258-71.
- ↑ Ringold S, Dennos AC, Kimura Y, et al. Disease recapture rates after medication discontinuation and flare in juvenile idiopathic arthritis: an observational study within the Childhood Arthritis and Rheumatology Research Alliance registry. Arthritis Care Res (Hoboken) 2023; 75: 715 23.
- ↑ Towe C, Grom AA, Schulert GS. Diagnosis and management of the systemic juvenile idiopathic arthritis patient with emerging lung disease. Paediatr Drugs 2023; 25: 649-58.
- ↑ Wobma H, Arvila SR, Taylor ML, et al. Incidence and risk factors for eosinophilia and lung disease in biologic-exposed children with systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2023; 75: 2063-72.
- ↑ Saper VE, Tian L, Verstegen RHJ, et al. Interleukin (IL)-1/IL-6-inhibitor-associat ed drug reaction with eosinophilia and systemic symptoms (DReSS) in systemic inflammatory illnesses. J Allergy Clin Im munol Pract 2024; 12(11): 2996-3013.e7.
- ↑ Sandborg CI, Schulert GS, Kimura Y. Juvenile Idiopathic Arthritis. N Engl J Med. 2025;392:XXX–XXX. doi:10.1056/NEJMra2402073.
- ↑ Horneff G, Klein A, Klotsche J, et al. Update on biologic and targeted synthetic therapies for juvenile idiopathic arthritis. Ann Rheum Dis. 2023;82:1038–1046.
- ↑ De Benedetti F, Brunner HI, Ruperto N. Targeted therapies in juvenile idiopathic arthritis: current status and future directions. Lancet Rheumatol. 2022;4:e204–e216.
- ↑ Beukelman T, Ringold S. Precision medicine and treat-to-target strategies in juvenile idiopathic arthritis. Rheum Dis Clin North Am. 2023;49:523–540.